Clinical trialRSSYesterday
Researchers tested a new inhaled medicine called LAM-001 on patients with two types of lung disease: pulmonary hypertension combined with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). All patients who finished the small early-stage trial showed significant improvement in their symptoms. The results are encouraging enough that the company plans to continue testing this medicine.
WHY IT MATTERSIf LAM-001 proves effective in larger trials, it could offer a new treatment option for PH-ILD patients, a condition with limited approved therapies that causes progressive breathing difficulty and high pressure in lung blood vessels.
ResearchRSS2 days ago
Scientists used artificial intelligence to analyze medical records from hundreds of PAH patients and created a new tool that can predict whether a patient's condition will get worse in the future. PAH is a serious lung disease where blood vessels in the lungs become narrowed, making it hard for the heart to pump blood. This new AI system could help doctors catch problems earlier and adjust treatment plans before patients get sicker.
WHY IT MATTERSIf this AI tool becomes available in clinical practice, PAH patients could receive earlier warning signs of disease worsening, allowing doctors to intensify treatment before serious complications develop.
ResearchRSS4 days ago
Researchers in China used artificial intelligence to study the genes involved in pulmonary arterial hypertension (PAH), a serious condition where blood vessels in the lungs become narrowed and stiff. They identified two genes called ATP1B1 and HP that appear to be important in causing PAH. These genes could potentially become targets for new treatments in the future.
WHY IT MATTERSIf ATP1B1 and HP prove to be valid therapeutic targets, they could lead to new treatment options for PAH patients who currently have limited medication choices.
PipelineRSSMay 11
Two companies are working together to create a new way to take a PAH medicine. Instead of swallowing a pill, patients would inhale a dry powder that goes straight to the lungs. This gives people with pulmonary arterial hypertension another option for how they receive their treatment.
WHY IT MATTERSIf approved, inhaled ralinepag could offer PAH patients a non-invasive alternative to oral tablets, potentially improving drug delivery directly to affected lung tissue and reducing systemic side effects.
ResearchRSSMay 6
Scientists in China discovered four genes—COL1A1, MYL9, COL1A2, and TPM2—that may be responsible for causing idiopathic pulmonary arterial hypertension (PAH), a rare lung disease where blood vessels in the lungs become abnormally narrow and stiff. They used computer analysis to identify these genes and then tested their findings in cells and animals to confirm the results. These genes could become targets for new treatments in the future.
WHY IT MATTERSIdentifying these four driver genes gives researchers specific targets to develop new treatments for idiopathic PAH, a disease with limited treatment options and poor survival rates if left untreated.
ResearchRSSMay 4
Researchers in China created a new drug called CPD1 that belongs to a class of medications called PDE5 inhibitors, which are already used to treat high blood pressure in the lungs (pulmonary arterial hypertension). In early testing on rats with this condition, CPD1 reduced disease severity and helped scientists understand how the drug works at a molecular level.
WHY IT MATTERSThis research identifies a potential new treatment option for PAH patients, though it remains in early preclinical stages and is years away from human testing or availability.
ResearchRSSApr 27
A new study found that people with pulmonary arterial hypertension (PAH), a rare lung disease, often develop irregular heartbeats like atrial fibrillation and atrial flutter. These irregular heartbeats, where the heart beats too fast or out of sync, were linked to worse health outcomes in PAH patients. This research helps doctors understand an important complication that affects many people living with PAH.
WHY IT MATTERSIf you have PAH, knowing that irregular heartbeats are common and linked to higher risks means you should ask your doctor about screening for arrhythmias and what symptoms to watch for.
ResearchRSSApr 22
Scientists found that a gene called RUNX1 might help doctors predict when patients with pulmonary arterial hypertension (PAH) — a serious lung disease that makes it hard to pump blood — could develop heart problems. When the right side of the heart weakens in PAH patients, it becomes very dangerous. This discovery could help doctors catch and treat these heart problems earlier.
WHY IT MATTERSIf RUNX1 becomes a validated biomarker, PAH patients could receive earlier interventions to prevent right heart failure, potentially improving survival and quality of life before irreversible damage occurs.
NewsRSSApr 22
This article is a quiz that tests what you know about riociguat, a medication used to treat pulmonary arterial hypertension (PAH). PAH is a rare condition where blood vessels in the lungs become narrowed, making it harder for the heart to pump blood through them. The quiz helps patients and caregivers learn more about how this treatment works.
WHY IT MATTERSUnderstanding how riociguat works and its role in PAH treatment can help patients make informed decisions about their care and have more meaningful conversations with their doctors about their treatment options.
Clinical trialRSSApr 22
A new clinical trial has started testing a drug called IKT-001 in people with pulmonary arterial hypertension (PAH), a rare condition where blood vessels in the lungs become narrowed and make it hard for the heart to pump blood. This is a large Phase 3 trial, which is a late-stage test that happens before a drug might be approved. Nearly 500 adults will participate to see if this drug works better than current treatments.
WHY IT MATTERSIf you have PAH and are already on stable treatment, you may be eligible to join the IMPROVE-PAH trial and potentially access IKT-001 before it becomes widely available.
NewsRSSApr 22
Orenitram is a pill form of a medicine called treprostinil that helps people with pulmonary arterial hypertension (a serious lung condition where blood vessels in the lungs become too narrow). You take it by mouth 2-3 times a day with food. This medicine helps patients exercise better and slows down how fast their disease gets worse.
WHY IT MATTERSThis oral option gives PAH patients an alternative to injected or inhaled treprostinil, making treatment more convenient for daily management.
ResearchRSSApr 22
Researchers found that data from smartphones and wearable devices, collected over several years through a health app, can help doctors identify people with a rare lung disease called idiopathic pulmonary arterial hypertension (IPAH) earlier than before. The study used information like heart rate and activity levels from the My Heart Counts app to spot differences between people with IPAH and healthy people. This discovery could lead to faster diagnosis of this serious condition.
WHY IT MATTERSEarlier detection of IPAH could allow patients to start treatment sooner, potentially slowing disease progression and improving outcomes for this condition that currently has no cure.